The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Natus Medical met expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP earnings per share dropped to a loss.
Gross margins expanded, operating margins contracted, net margins dropped.
Natus Medical booked revenue of $80.7 million. The three analysts polled by S&P Capital IQ hoped for revenue of $81.4 million on the same basis. GAAP reported sales were 57% higher than the prior-year quarter's $51.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.07. The two earnings estimates compiled by S&P Capital IQ anticipated $0.14 per share. GAAP EPS were -$0.07 for Q3 compared to $0.01 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 54.8%, 110 basis points better than the prior-year quarter. Operating margin was -6.0%, 650 basis points worse than the prior-year quarter. Net margin was -2.4%, 270 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $95.9 million. On the bottom line, the average EPS estimate is $0.29.
Next year's average estimate for revenue is $296.1 million. The average EPS estimate is $0.60.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,256 members out of 1,287 rating the stock outperform, and 31 members rating it underperform. Among 361 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 351 give Natus Medical a green thumbs-up, and 10 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Natus Medical is hold, with an average price target of $13.50.
- Add Natus Medical to My Watchlist.